SEARCH

SEARCH BY CITATION

References

  • Evans MJ, Rollins SA, Wolff DW, Rother RP, Norin AJ, Therrien DM, Grijalva GA, Mueller JP, Nye SH, Squinto SP, et al (1995) In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol Immunol 32: 1183- 1195
  • Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, et al (2011) Complement blockade in severe Shiga-toxin-associated HUS. N Engl J Med, 364: 2561- 2563
  • Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, et al (2009) Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182: 6394- 6400
  • Würzner R, Schulze M, Happe L, Franzke A, Bieber FA, Oppermann M, Götze O (1991) Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm 8: 328- 340
  • Zimmerhackl LB, Hofer J, Cortina G, Mark W, Würzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W (2010) Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 362: 1746- 1748